ClinicalTrials.gg
CompletedNCT01101451Updated May 23, 2025Results posted

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

A Phase 3 interventional study of Cisplatin and External Beam Radiation Therapy in Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma and Cervical Squamous Cell Carcinoma, Not Otherwise Specified, sponsored by GOG Foundation. Completed at 719 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.

Sponsored by GOG Foundation · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies testing cisplatin in Uterine Cervical Neoplasms — 10 open to participants now, 11 under way, 3 of them phase 3. Cisplatin · Uterine Cervical Neoplasms.

Enrollment
11th of 73
340 · median 50
Started
2010
with 3 others
Phase 3
20 of 80
3 open now
Registered
47th of 80
by date
Lead sponsor
2 of 80
GOG Foundation

Among the 80 studies testing cisplatin in Uterine Cervical Neoplasms, this one is the 11th largest by enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2010, is one of 20 in phase 3, and was the 47th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

10 of the 80 studies testing cisplatin in Uterine Cervical Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing cisplatin in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

This randomized phase III trial studies radiation therapy with chemotherapy to see how well they work compared to radiation therapy alone in treating patients with stage I-IIA cervical cancer who previously underwent surgery. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving radiation therapy together with chemotherapy is more effective than radiation therapy alone in treating patients with cervical cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine if post-operative adjuvant chemo-radiation therapy (CRT) can significantly improve recurrence-free survival (RFS) when compared to radiation therapy (RT) alone in stage I-IIA cervical cancer patients with intermediate-risk factors after treatment with radical hysterectomy.

SECONDARY OBJECTIVES:

I. To determine whether post-operative adjuvant CRT can improve overall survival (OS) when compared to RT alone in stage I-IIA cervical cancer patients with intermediate risk factors after treatment with radical hysterectomy.

II. To assess differences (across treatment arms) in incidence and severity of therapy attributed adverse events utilizing the active version of Common Terminology Criteria for Adverse Events (CTCAE).

III. To provide assessment of patient risk version (vs) benefit (positive study only).

QUALITY OF LIFE OBJECTIVE:

I. To determine whether post-operative adjuvant CRT improves the health-related quality-of-life (QOL) (compared to RT alone) as measured by Functional Assessment of Cancer Therapy-Cervix (FACT-Cx) Trial Outcome Index (TOI) and produce favorable toxicity profiles (with particular focus on treatment related genitourinary, gastrointestinal, neurological, pain and sexual adverse events).

TRANSLATIONAL RESEARCH OBJECTIVES:

I. To bank archival tumor tissue for research studies, including studies that evaluate the association between biomarkers, RFS, OS, and clinical-surgical-pathologic characteristics in patients randomized to post-operative adjuvant CRT compared to RT alone.

II. To bank deoxyribonucleic acid (DNA) from whole blood for research studies, including studies that evaluate associations between single nucleotide polymorphisms (SNPs), and measures of clinical outcome, including RFS, OS, and adverse events in patients randomized to post-operative adjuvant CRT compared to RT alone.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients undergo pelvic external-beam radiation therapy (EBRT) or intensity-modulated radiation therapy (IMRT) 5 days a week for 5.5 weeks.

ARM II: Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

03

Conditions studied

  • Cervical Adenocarcinoma
  • Cervical Adenosquamous Carcinoma
  • Cervical Squamous Cell Carcinoma, Not Otherwise Specified
  • Stage I Cervical Cancer AJCC v6 and v7
  • Stage IA Cervical Cancer AJCC v6 and v7
  • Stage IB Cervical Cancer AJCC v6 and v7
  • Stage IIA Cervical Cancer AJCC v7
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven primary cervical cancer I-IIA with squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma initially treated with a standard radical hysterectomy with pelvic lymphadenectomy
  • Patients with the following characteristics (depth of stromal invasion and lymphovascular space involvement to be pathologically confirmed):

    • Positive capillary-lymphovascular space involvement and one of the following:

      • Deep third penetration
      • Middle third penetration, clinical tumor >= 2 cm
      • Superficial third penetration, clinical tumor >= 5 cm
    • Negative capillary-lymphatic space involvement

      • Middle or deep third penetration, clinical tumor >= 4 cm
  • (ANC) >= 1,500/mcl
  • >= 100,000/mcl
  • Creatinine =\< (ULN) or calculated >= 60 mL/min
  • =\< 1.5 x normal
  • Alkaline phosphate =\< 3 x normal
  • Serum glutamic oxaloacetic transaminase () =\< 3 x normal
  • Gynecologic Oncology Group (GOG) performance status 0, 1, 2
  • Patients should not be randomized less than 3 weeks post-surgery but will not be acceptable for randomization more than 8 weeks post-surgery
  • Patients who have met the pre-entry requirements
  • Patients must have signed an approved and authorization permitting release of personal health information

Exclusion criteria

Exclusion Criteria:

  • Patients with tumor in the parametria, pelvic lymph nodes or any other extra uterine site or with positive surgical margins
  • Patients with septicemia or severe infection
  • Patients with intestinal obstruction or gastrointestinal bleeding
  • Patients with postoperative fistula
  • Patients with cervix cancer who have received any previous radiation or chemotherapy
  • Patients whose circumstances do not permit completion of the study or the required follow-up
  • Patients with renal abnormalities requiring modification of radiation field (pelvic kidney, renal transplant, etc.)
  • Patients with GOG performance status of 3 or 4
  • Patients with a history of other invasive , with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
340 participants (actual)

Study arms

  • Active comparator
    Arm I (EBRT, IMRT)

    Patients undergo pelvic EBRT or IMRT once daily, 5 days a week, for 5.5 weeks.

    Radiation: External Beam Radiation Therapy · Radiation: Intensity-Modulated Radiation Therapy · Other: Laboratory Biomarker Analysis · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

  • Experimental
    Arm II (cisplatin, EBRT, IMRT)

    Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

    Drug: Cisplatin · Radiation: External Beam Radiation Therapy · Radiation: Intensity-Modulated Radiation Therapy · Other: Laboratory Biomarker Analysis · Other: Quality-of-Life Assessment · Other: Questionnaire Administration

Interventions

  • Given IV

    Also known as: Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone''s Chloride, Peyrone''s Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin

  • RadiationExternal Beam Radiation Therapy

    Undergo radiotherapy

    Also known as: Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam

  • RadiationIntensity-Modulated Radiation Therapy

    Undergo radiotherapy

    Also known as: IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • OtherQuality-of-Life Assessment

    Ancillary studies

    Also known as: Quality of Life Assessment

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Recurrence-free Survival (RFS) Rate at 3-years

    Estimate for probability of RFS at 3 years using Kaplan-Meier method, where RFS is defined as time from protocol registration (and randomization) to the date of first documented recurrence, death, or the date of last contact, whichever occurs first. Patients without recurrence or death were censored at the date of last contact.

    Time frame: 3 years from randomization

Secondary outcomes

  1. Overall Survival (OS) Rate at 3-years

    Estimate for probability of overall survival at 3 years by Kaplan-Meier method, where overall survival is defined as the time from randomization to time of death due to any cause or the date of last contact, whichever occurs first.

    Time frame: 3 years from randomization

  2. Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period.

    Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v4.0.

    Time frame: During treatment period and up to 21 days after stopping the study treatment. The median treatment duration was 39 days.

  3. Patient Risk-benefit

    The reporting group (2) did not demonstrate improved RFS compared to the reporting group (1) at the pre-specified significance level. Per the protocol, patient risk-benefit will be assessed only for a positive study. This is not assessed due to non-positive study per the protocol.

    Time frame: up to 11 years

  4. Quality of Life (QOL) as Measured With the FACT-Cx TOI

    The patient-reported QOL is assessed with the Trial Outcome Index of the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx TOI). The FACT-Cx TOI is ranged 0-116 and a larger FACT-Cx TOI score suggests a favorable QoL.

    Time frame: 1. Pre-treatment (baseline), 2. 3 weeks following the first day of treatment, 3. 7 weeks following the first day of treatment, 4. 36 weeks following the first day of treatment.

Other outcomes

  1. Treatment Compliance

    Assessed by the number of cycles and amount of chemoradiotherapy administered, treatment span, incidence and duration of treatment delays, reason for delays, and reason why off study therapy.

    Time frame: Up to 11 years

  2. Site(s) of Recurrence

    The site(s) of first disease recurrence will be classified as: pelvic-only, extra-pelvic-only or pelvic-and-extra-pelvic and tabulated by treatment group. The test of the hypothesis that the probability of local failure is independent of randomized treatment will be assessed with exact logistic regression adjusted know prognostic factors.

    Time frame: Up to 11 years

  3. Local Control

    Assessed with Exact Logistic Regression adjusted known prognostic factors.

    Time frame: Up to 11 years

07

Results

Posted May 1, 2025

Participant flow

GOG-0263 opened to accrual on April 12, 2010, and closed to accrual on April 11, 2022.

Participant flow — Overall Study
MilestoneArm I (Radiation)Arm II (Cisplatin + Radiation)
Started172168
Completed158153
Not completed1415
Withdrew: Eligible and never treated05
Withdrew: Ineligible and treated128
Withdrew: Ineligible and never treated22

Outcome measures

PrimaryRecurrence-free Survival (RFS) Rate at 3-years

Estimate for probability of RFS at 3 years using Kaplan-Meier method, where RFS is defined as time from protocol registration (and randomization) to the date of first documented recurrence, death, or the date of last contact, whichever occurs first. Patients without recurrence or death were censored at the date of last contact.

Time frame:
3 years from randomization
Reported as:
Number · percentage of participants
Recurrence-free Survival (RFS) Rate at 3-years
percentage of participantsArm I (Radiation)Arm II (Cisplatin + Radiation)
Recurrence-free Survival (RFS) Rate at 3-years85.4 (79 to 90)88.5 (82 to 93)
Statistical analysis
  • Arm I (Radiation) vs Arm II (Cisplatin + Radiation) · Log Rank · p = 0.0927 (the pre_specified nominal significance level was 0.0451 (one sided).) · Hazard ratio (hr): 0.6976 · 95% CI 0.408 to 1.192The RFS hazard ratio estimate is for reporting group 2 vs reporting group 1.
SecondaryOverall Survival (OS) Rate at 3-years

Estimate for probability of overall survival at 3 years by Kaplan-Meier method, where overall survival is defined as the time from randomization to time of death due to any cause or the date of last contact, whichever occurs first.

Time frame:
3 years from randomization
Reported as:
Number · percentage of participants
Overall Survival (OS) Rate at 3-years
percentage of participantsArm I (Radiation)Arm II (Cisplatin + Radiation)
Overall Survival (OS) Rate at 3-years90.3 (84 to 94)97.2 (93 to 99)
Statistical analysis
  • Arm I (Radiation) vs Arm II (Cisplatin + Radiation) · Hazard ratio (hr): 0.586 · 95% CI 0.286 to 1.199The OS hazard ratio estimate is for reporting group 2 vs reporting group 1.
SecondaryNumber of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period.

Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v4.0.

Time frame:
During treatment period and up to 21 days after stopping the study treatment. The median treatment duration was 39 days.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (Grade 3 or Higher) During Treatment Period.
ParticipantsArm I (Radiation)Arm II (Cisplatin + Radiation)
Anemia16
Other blood/lymphatics04
White blood cell decreased345
Platelet count decreased04
Neutrophil count decreased227
Other investigations78
Gastrointestinal1012
General and administration site23
Infections/infestations44
Metabolism/nutrition07
Musculoskeletal/connective tissue10
Nervous system21
Psychiatric11
Renal/urinary22
Reproductive/breast21
Skin/subcutaneous03
Vascular disorders01
SecondaryPatient Risk-benefit

The reporting group (2) did not demonstrate improved RFS compared to the reporting group (1) at the pre-specified significance level. Per the protocol, patient risk-benefit will be assessed only for a positive study. This is not assessed due to non-positive study per the protocol.

Time frame:
up to 11 years

No measurements were reported for this outcome.

SecondaryQuality of Life (QOL) as Measured With the FACT-Cx TOI

The patient-reported QOL is assessed with the Trial Outcome Index of the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx TOI). The FACT-Cx TOI is ranged 0-116 and a larger FACT-Cx TOI score suggests a favorable QoL.

Time frame:
1. Pre-treatment (baseline), 2. 3 weeks following the first day of treatment, 3. 7 weeks following the first day of treatment, 4. 36 weeks following the first day of treatment.
Reported as:
Mean · units on a scale
Quality of Life (QOL) as Measured With the FACT-Cx TOI
units on a scaleArm I (Radiation)Arm II (Cisplatin + Radiation)
Baseline83.5 ± 15.480.1 ± 15.4
3 weeks79.0 ± 16.471.4 ± 15.3
7 weeks80.1 ± 17.071.8 ± 17.1
36 weeks88.8 ± 15.588.1 ± 12.3
Other pre-specifiedTreatment Compliance

Assessed by the number of cycles and amount of chemoradiotherapy administered, treatment span, incidence and duration of treatment delays, reason for delays, and reason why off study therapy.

Time frame:
Up to 11 years

Results for this outcome have not been posted.

Other pre-specifiedSite(s) of Recurrence

The site(s) of first disease recurrence will be classified as: pelvic-only, extra-pelvic-only or pelvic-and-extra-pelvic and tabulated by treatment group. The test of the hypothesis that the probability of local failure is independent of randomized treatment will be assessed with exact logistic regression adjusted know prognostic factors.

Time frame:
Up to 11 years

Results for this outcome have not been posted.

Other pre-specifiedLocal Control

Assessed with Exact Logistic Regression adjusted known prognostic factors.

Time frame:
Up to 11 years

Results for this outcome have not been posted.

Adverse events

Collected over During treatment period and up to 21 days after stopping the study treatment. The median treatment duration was 39 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm I (Radiation)20/158 (12.7%)7/170 (4.1%)140/170 (82.4%)
Arm II (Cisplatin + Radiation)12/158 (7.6%)9/161 (5.6%)158/161 (98.1%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventArm I (Radiation)Arm II (Cisplatin + Radiation)
NauseaGastrointestinal disorders0/1702/161
White Blood Cell DecreasedInvestigations0/1702/161
Blood And Lymphatic System Disorders - OtherBlood and lymphatic system disorders0/1701/161
VomitingGastrointestinal disorders0/1701/161
HypomagnesemiaMetabolism and nutrition disorders0/1701/161
HypokalemiaMetabolism and nutrition disorders0/1701/161
SeizureNervous system disorders0/1701/161
Urinary Tract ObstructionRenal and urinary disorders1/1701/161
Colonic FistulaGastrointestinal disorders1/1700/161
Abdominal PainGastrointestinal disorders1/1700/161
Most frequent other events
Showing 10 of 184
Most frequent other events
EventArm I (Radiation)Arm II (Cisplatin + Radiation)
White Blood Cell DecreasedInvestigations73/170121/161
NauseaGastrointestinal disorders61/170117/161
AnemiaBlood and lymphatic system disorders63/17095/161
Neutrophil Count DecreasedInvestigations36/17088/161
DiarrheaGastrointestinal disorders76/17078/161
FatigueGeneral disorders46/17074/161
Platelet Count DecreasedInvestigations19/17073/161
ConstipationGastrointestinal disorders26/17063/161
AnorexiaMetabolism and nutrition disorders18/17048/161
VomitingGastrointestinal disorders14/17037/161

Baseline characteristics

Eligible

Age, Customized
Age, Customized(Participants)Arm I (Radiation)Arm II (Cisplatin + Radiation)Total
20-29 years325
30-39 years284775
40-49 years6253115
50-59 years463379
60-69 years131730
70-79 years5611
>= 80 years101
Sex: Female, Male
Sex: Female, Male(Participants)Arm I (Radiation)Arm II (Cisplatin + Radiation)Total
Female158158316
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm I (Radiation)Arm II (Cisplatin + Radiation)Total
Hispanic or Latino121527
Not Hispanic or Latino142142284
Unknown or Not Reported415
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm I (Radiation)Arm II (Cisplatin + Radiation)Total
American Indian or Alaska Native224
Asian7987166
Native Hawaiian or Other Pacific Islander101
Black or African American12517
White6258120
More than one race000
Unknown or Not Reported268
08

Study locations

719 sites
  • Anchorage Associates in Radiation Medicine
    Anchorage, Alaska 98508, United States
  • Anchorage Radiation Therapy Center
    Anchorage, Alaska 99504, United States
  • Alaska Breast Care and Surgery LLC
    Anchorage, Alaska 99508, United States
  • Alaska Oncology and Hematology LLC
    Anchorage, Alaska 99508, United States
  • Alaska Regional Hospital
    Anchorage, Alaska 99508, United States
  • Alaska Women's Cancer Care
    Anchorage, Alaska 99508, United States
  • Anchorage Oncology Centre
    Anchorage, Alaska 99508, United States
  • Katmai Oncology Group
    Anchorage, Alaska 99508, United States
  • Providence Alaska Medical Center
    Anchorage, Alaska 99508, United States
  • Fairbanks Memorial Hospital
    Fairbanks, Alaska 99701, United States
  • Cancer Center at Saint Joseph's
    Phoenix, Arizona 85004, United States
  • Saint Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
  • Mercy Hospital Fort Smith
    Fort Smith, Arkansas 72903, United States
  • CHI Saint Vincent Cancer Center Hot Springs
    Hot Springs, Arkansas 71913, United States
  • PCR Oncology
    Arroyo Grande, California 93420, United States
  • Sutter Auburn Faith Hospital
    Auburn, California 95602, United States
  • Sutter Cancer Centers Radiation Oncology Services-Auburn
    Auburn, California 95603, United States
  • Alta Bates Summit Medical Center-Herrick Campus
    Berkeley, California 94704, United States
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center
    Burbank, California 91505, United States
  • Mills-Peninsula Medical Center
    Burlingame, California 94010, United States
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park
    Cameron Park, California 95682, United States
  • Mercy San Juan Medical Center
    Carmichael, California 95608, United States
  • Eden Hospital Medical Center
    Castro Valley, California 94546, United States
  • John Muir Medical Center-Concord Campus
    Concord, California 94520, United States
  • Sutter Davis Hospital
    Davis, California 95616, United States
  • Mercy Cancer Center - Elk Grove
    Elk Grove, California 95758, United States
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • Los Angeles County-USC Medical Center
    Los Angeles, California 90033, United States
  • USC / Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Memorial Medical Center
    Modesto, California 95355, United States
  • Palo Alto Medical Foundation-Camino Division
    Mountain View, California 94040, United States
  • Palo Alto Medical Foundation-Gynecologic Oncology
    Mountain View, California 94040, United States
  • Sutter Cancer Research Consortium
    Novato, California 94945, United States
  • UC Irvine Health/Chao Family Comprehensive Cancer Center
    Orange, California 92868, United States
  • Palo Alto Medical Foundation Health Care
    Palo Alto, California 94301, United States
  • Pomona Valley Hospital Medical Center
    Pomona, California 91767, United States
  • Mercy Cancer Center - Rocklin
    Rocklin, California 95765, United States
  • Sutter Cancer Centers Radiation Oncology Services-Roseville
    Roseville, California 95661, United States
  • Sutter Roseville Medical Center
    Roseville, California 95661, United States
  • Mercy Cancer Center - Sacramento
    Sacramento, California 95816, United States
  • Sutter Medical Center Sacramento
    Sacramento, California 95816, United States
  • California Pacific Medical Center-Pacific Campus
    San Francisco, California 94115, United States
  • Pacific Central Coast Health Center-San Luis Obispo
    San Luis Obispo, California 93401, United States
  • Palo Alto Medical Foundation-Santa Cruz
    Santa Cruz, California 95065, United States
  • Mission Hope Medical Oncology - Santa Maria
    Santa Maria, California 93444, United States
  • Sutter Pacific Medical Foundation
    Santa Rosa, California 95403, United States
  • Palo Alto Medical Foundation-Sunnyvale
    Sunnyvale, California 94086, United States
  • Olive View-University of California Los Angeles Medical Center
    Sylmar, California 91342, United States
  • Sutter Cancer Centers Radiation Oncology Services-Vacaville
    Vacaville, California 95687, United States
  • Sutter Solano Medical Center/Cancer Center
    Vallejo, California 94589, United States
  • John Muir Medical Center-Walnut Creek
    Walnut Creek, California 94598, United States
  • Woodland Memorial Hospital
    Woodland, California 95695, United States
  • Rocky Mountain Cancer Centers-Aurora
    Aurora, Colorado 80012, United States
  • The Medical Center of Aurora
    Aurora, Colorado 80012, United States
  • Boulder Community Hospital
    Boulder, Colorado 80301, United States
  • Boulder Community Foothills Hospital
    Boulder, Colorado 80303, United States
  • Rocky Mountain Cancer Centers-Boulder
    Boulder, Colorado 80304, United States
  • Penrose-Saint Francis Healthcare
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Cancer Centers-Penrose
    Colorado Springs, Colorado 80907, United States
  • Porter Adventist Hospital
    Denver, Colorado 80210, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Presbyterian - Saint Lukes Medical Center - Health One
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Centers-Midtown
    Denver, Colorado 80218, United States
  • SCL Health Saint Joseph Hospital
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Centers-Rose
    Denver, Colorado 80220, United States
  • Rose Medical Center
    Denver, Colorado 80220, United States
  • Mercy Medical Center
    Durango, Colorado 81301, United States
  • Southwest Oncology PC
    Durango, Colorado 81301, United States
  • Mountain Blue Cancer Care Center - Swedish
    Englewood, Colorado 80113, United States
  • Swedish Medical Center
    Englewood, Colorado 80113, United States
  • Mountain Blue Cancer Care Center
    Golden, Colorado 80401, United States
  • Saint Mary's Hospital and Regional Medical Center
    Grand Junction, Colorado 81501, United States
  • North Colorado Medical Center
    Greeley, Colorado 80631, United States
  • Rocky Mountain Cancer Centers-Greenwood Village
    Greenwood Village, Colorado 80111, United States
  • Rocky Mountain Cancer Centers-Lakewood
    Lakewood, Colorado 80228, United States
  • Saint Anthony Hospital
    Lakewood, Colorado 80228, United States
  • Rocky Mountain Cancer Centers-Littleton
    Littleton, Colorado 80120, United States
  • Littleton Adventist Hospital
    Littleton, Colorado 80122, United States
  • Rocky Mountain Cancer Centers-Sky Ridge
    Lone Tree, Colorado 80124, United States
  • Sky Ridge Medical Center
    Lone Tree, Colorado 80124, United States
  • Longmont United Hospital
    Longmont, Colorado 80501, United States
  • Rocky Mountain Cancer Centers-Longmont
    Longmont, Colorado 80501, United States
  • McKee Medical Center
    Loveland, Colorado 80539, United States
  • Parker Adventist Hospital
    Parker, Colorado 80138, United States
  • Rocky Mountain Cancer Centers-Parker
    Parker, Colorado 80138, United States
  • Saint Mary Corwin Medical Center
    Pueblo, Colorado 81004, United States
  • Rocky Mountain Cancer Centers - Pueblo
    Pueblo, Colorado 81008, United States
  • Rocky Mountain Cancer Centers-Thornton
    Thornton, Colorado 80260, United States
  • SCL Health Lutheran Medical Center
    Wheat Ridge, Colorado 80033, United States
  • Hartford Hospital
    Hartford, Connecticut 06102, United States
  • Smilow Cancer Hospital Care Center at Saint Francis
    Hartford, Connecticut 06105, United States
  • The Hospital of Central Connecticut
    New Britain, Connecticut 06050, United States
  • Yale University
    New Haven, Connecticut 06520, United States
  • Sibley Memorial Hospital
    Washington, District of Columbia 20016, United States
  • AdventHealth Altamonte
    Altamonte Springs, Florida 32701, United States
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
    Deerfield Beach, Florida 33442, United States
  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
  • AdventHealth Kissimmee
    Kissimmee, Florida 34744, United States
  • Jackson Memorial Hospital-Holtz Children's Hospital
    Miami, Florida 33136, United States

Showing the first 100 of 719 sites across 3 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kim H, Park W, Kim YS, Kim YJ. Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor. J Gynecol Oncol. 2020 May;31(3):e35. doi: 10.3802/jgo.2020.31.e35. Epub 2019 Nov 21. PubMed 31912685 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2010 to primary completion in Jan 2024, 165 months.

Results were first posted in May 2025, 1 year 3 months after primary completion.

Of 53 non-industry phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 107. This study's 165 months is above that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2010
First posted
Apr 12, 2010
StartActual
Apr 12, 2010
Primary completionActual
Jan 15, 2024
CompletionActual
Apr 2, 2024
Results first posted
May 1, 2025
Last update
May 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01101451
Lead sponsor
GOG Foundation
Responsible party
Sponsor
First posted
Apr 12, 2010
Start date
Apr 12, 2010
Primary completion
Jan 15, 2024
Completion
Apr 2, 2024
Results posted
May 1, 2025
Last update
May 23, 2025

Study contacts

Sang Y Ryu
principal investigator · NRG Oncology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cisplatin

Start the discussion